FDA — authorised 20 April 1977
- Application: ANDA085008
- Marketing authorisation holder: PVT FORM
- Local brand name: FEMOGEN
- Indication: TABLET — ORAL
- Status: approved
🇺🇸 Menest in United States
FDA authorised Menest on 20 April 1977
Marketing authorisations
FDA — authorised 20 April 1977
- Application: ANDA085007
- Marketing authorisation holder: PVT FORM
- Local brand name: FEMOGEN
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 28 September 1977
- Application: ANDA083376
- Marketing authorisation holder: ROCHE PALO
- Local brand name: EVEX
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 28 September 1977
- Application: ANDA084215
- Marketing authorisation holder: ROCHE PALO
- Local brand name: EVEX
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA085076
- Marketing authorisation holder: PVT FORM
- Local brand name: FEMOGEN
- Indication: TABLET — ORAL
- Status: approved
FDA
- Status: approved
FDA
- Application: ANDA086715
- Marketing authorisation holder: SOLVAY
- Local brand name: ESTRATAB
- Indication: TABLET — ORAL
- Status: approved
Pricing & reimbursement
- annual_list: USD 80000.00 per year
Menest in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United States
Frequently asked questions
Is Menest approved in United States?
Yes. FDA authorised it on 20 April 1977; FDA authorised it on 20 April 1977; FDA authorised it on 28 September 1977.
Who is the marketing authorisation holder for Menest in United States?
PVT FORM holds the US marketing authorisation.
What does Menest cost in United States?
annual_list: USD 80000.00 per year. Final patient cost depends on reimbursement and any patient access scheme.